Mar. 18 at 12:56 PM
$GNPX On March 18, 2026, Genprex announced that its collaborators will present multiple posters at the 2026 American Association for Cancer Research Annual Meeting in San Diego, highlighting new preclinical data on Reqorsa gene therapy for lung cancer. The first study identified TROP2 and PTEN expression patterns as potential biomarkers of primary resistance to TUSC2 gene therapy in NSCLC models, suggesting a way to better select patients and tailor treatment strategies.
A second study in ALK-positive NSCLC cell, organoid, and mouse models showed that Quar Oze-mediated TUSC2 overexpression induces strong apoptosis and enhances the effect of the ALK inhibitor alectinib, including in models with acquired alectinib resistance. The combination therapy produced greater tumor shrinkage and survival benefits than alectinib alone, underscoring Reqorsa’s potential role as an adjunct treatment in resistant disease.
